ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,708.89
0.16%
US Tech 100
19,418.00
0.80%
다우존스 지수
41,996.56
-0.04%
Bitcoin
61,601.10
1.40%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Zentalis Pharmaceuticals Inc (ZNTL) 시세

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc (ZNTL)

NASDAQ
3.155
-0.045
( -1.41% )
업데이트: 00:09:21
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
3.155
매수가
3.15
매도가
3.16
거래량
153,219
3.09 일간 변동폭 3.25
2.83 52주 범위 21.34
market_cap
224.346M
전일 종가
3.20
개장가
3.24
최근 거래 시간
100
@
3.155
마지막 거래 시간
00:09:21
재정 규모
US$ 488,216
VWAP
3.1864
평균 볼륨(3m)
1,726,297
발행 주식
71,107,967
배당수익률
-
주가수익률
-0.77
주당순이익(EPS)
-4.11
매출
-
순이익
-292.19M

Zentalis Pharmaceuticals Inc 정보

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.zentalis.com
본부
Wilmington, Delaware, USA
설립됨
-
Zentalis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was US$3.20. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of US$ 2.83 to US$ 21.34.

Zentalis Pharmaceuticals currently has 71,107,967 shares in issue. The market capitalisation of Zentalis Pharmaceuticals is US$227.55 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.77.

ZNTL 최신 뉴스

추가 뉴스

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

17 9월 2024
PR Newswire (US)

Form 8-K - Current report

16 9월 2024
Edgar (US Regulatory)

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

16 9월 2024
GlobeNewswire Inc.

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

09 9월 2024
GlobeNewswire Inc.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

04 9월 2024
GlobeNewswire Inc.

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ:ZNTL) into...

20 8월 2024
Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

09 8월 2024
Edgar (US Regulatory)

Form 8-K - Current report

09 8월 2024
Edgar (US Regulatory)

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc...

09 8월 2024
GlobeNewswire Inc.

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

02 8월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.605-16.09042553193.763.953.0911681743.45365909CS
4-0.075-2.321981424153.235.442.9535350393.76188957CS
12-0.875-21.71215880894.035.442.8317262973.70478526CS
26-12.555-79.917250159115.7116.212.8315118825.35165428CS
52-16.275-83.762223365919.4321.342.8312455298.62292965CS
156-64.315-95.32384763667.4787.192.8381473018.74546765CS
260-21.535-87.221547185124.6987.192.8362996622.88510889CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PEVPhoenix Motor Inc
US$ 0.8698
(150.30%)
77.36M
BENFBeneficient
US$ 1.77
(48.74%)
89.79M
FORDForward Industries Inc
US$ 4.98
(42.29%)
15.47M
SNALSnail Inc
US$ 1.015
(39.63%)
3.32M
SOBRSOBR Safe Inc
US$ 5.98
(35.91%)
92.48k
ADDColor Star Technology Company Ltd
US$ 0.3211
(-28.64%)
5.15M
CETXCemtrex Inc
US$ 1.83
(-28.52%)
1.91M
LASELaser Photonics Corporation
US$ 6.92
(-24.62%)
752.15k
ELABElevai Labs Inc
US$ 0.1028
(-22.12%)
17.48M
LSBLakeShore Biopharma Company Ltd
US$ 5.45
(-20.09%)
30.84k
NCNCnoco noco Inc
US$ 0.1764
(33.03%)
118.96M
NVDANVIDIA Corporation
US$ 123.99
(0.93%)
102.5M
BENFBeneficient
US$ 1.77
(48.74%)
89.79M
SQQQProShares UltraPro Short QQQ
US$ 7.525
(-2.40%)
88.68M
PEVPhoenix Motor Inc
US$ 0.8698
(150.30%)
77.36M

ZNTL Discussion

게시물 보기
Awl416 Awl416 3 주 전
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
👍️0
glenn1919 glenn1919 3 주 전
ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 월 전
ZNTL under $4
👍️0
ANTADOG ANTADOG 4 년 전
We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
👍️0
ANTADOG ANTADOG 4 년 전
Added some 46's , nice chart reset, ANT
👍️0
ANTADOG ANTADOG 4 년 전
55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
👍️0
ANTADOG ANTADOG 4 년 전
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
👍️0
ANTADOG ANTADOG 4 년 전
NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
fyi ANT
👍️0
ANTADOG ANTADOG 4 년 전
New 52 week high at 52.09, i luv it, ANT
👍️0
ANTADOG ANTADOG 4 년 전
Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
fyi ANT
👍️0
ANTADOG ANTADOG 4 년 전
Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
👍️0
ANTADOG ANTADOG 4 년 전
promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
👍️0
crudeoil24 crudeoil24 5 년 전
ZNTL opens @ 25.20 >
👍️0
crudeoil24 crudeoil24 5 년 전
Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher

Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2020 06:08 ET (10:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
👍️0
crudeoil24 crudeoil24 5 년 전
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
👍️0

최근 히스토리

NASDAQ
ZNTL
Zentalis Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유